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ABSTRACT The conventional vaccines currently being used to deal with influenza are based on a virus obtained in 
chicken embryos or its components. The high variability of the major immunogenic surface proteins – hemaggluti-
nin and neuraminidase–require the development of strain-specific vaccines that match the antigenic specificity of a 
newly emerging virus. Recombinant vaccines based on single viral proteins that could be easily produced in standard 
expression systems are attractive alternatives to traditional influenza vaccines. We constructed recombinant nanosized 
virus-like particles based on a nuclear antigen of the hepatitis B virus. These particles expose on the surface the extra-
cellular domain of the M2 protein of the highly pathogenic A(H1N1) 2009 influenza virus. The methods of production 
of these virus-like particles in Escherichia coli and their purification were developed. Experiments on animals show 
that M2sHBc particles are highly immunogenic in mice and provide complete protection against the lethal influenza 
challenge.
KEYWORDS influenza, vaccine, M2 protein, nanoparticle, HBc antigen.
ABBREVIATIONS M2e – extracellular domain of Influenza virus M2 protein, HBc – nuclear antigen of hepatitis B virus, 
M2sHBc – hybrid protein including M2e of the swine flu virus and HBc, PCR – polymerase chain reaction, , PBS-phos-
phate buffered saline, TMB – tetramethylbenzidine, LD50 – dose corresponding to 50% lethality rate, ELISA – enzyme-
-linked immunosorbent assay, FCS – fetal calf serum
INTRODUCTION:
Influenza is the most common viral disease in humans and 
animals. Type A influenza viruses vary in their degrees of 
pathogenicity. In recent years, the H5N1strain has caused 
local outbreaks of the disease with a high morbidity rate in 
Southeast Asia. The H1N1 virus originating in swine was be-
hind the flu pandemic that lasted from 2009 to 2010, with an 
unexpectedly high morbidity rate among middle-aged and 
high-risk individuals. Given its large amount of phenotypic 
attributes and its phylogenic origin, the H1N1 virus is akin 
to the virus that was deemed responsible for the Spanish Flu 
epidemic that lasted between 1918 and 1920. These character-
istics provide evidence of a possible return of a highly patho-
genic virus into circulation throughout the human population. 
The current influenza vaccines are based on a virus obtained 
from chicken embryos, or from its components [1]. The high 
variability of the viral surface proteins, hemagglutinin and 
neuraminidase, leads to the appearance of an epidemic strain 
every 1-2 years [2], which requires the development of a 
“standard” strain-specific vaccine at the same rate. 
One of the potential causes of antigen variability in the 
human influenza virus is its recombination (reassertion) with 
animal flu viruses, which can lead to the appearance of a new, 
highly pathogenic recombinant virus unfamiliar to the hu-
man immune system and, therefore, carrying the risk of a 
pandemic. At the same time, the development of a traditional 
vaccine for new strains requires a relatively extended period 
of time (6 to 9 months), during which the appearance of the 
new pandemic-causing strain could claim many casualties. 
As previously stated, the novel pathogenic strain responsible 
for the 2009 pandemic belongs to the H1N1 class, based on 
sequences coding of its hemagglutinin and neuraminidase.
Recombinant vaccines are alternatives to traditional meth-
ods, and they are based on specific viral proteins. The for-
mulation of these novel vaccines may be achieved in stand-
ard producing organisms, such as bacteria or yeast. The use 
of recombinant vaccines not only eliminates the industry’s 
dependence on chicken embryos and addresses the general 
safety concerns associated with vaccines based on the whole 
pathogen [3], but also creates an opportunity for the devel-
opment of “universal” vaccines with the use of conservative 
viral proteins. Moreover, this type of approach allows to pro-
duce these vaccines at high speed while “overlapping” the 
antigen properties of several pandemic viruses. 72 | ACTA NATURAE |  VOL. 2  № 2 (5)  2010
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W. Fiers et al. (University of Ghent) analyzed the possibil-
ity of developing a universal influenza vaccine based on the 
extracellular domain of the M2 protein of the influenza virus 
[4, 5]. M2 is a small transmembrane protein (97 amino acid 
residues) present in small amounts within the virion, yet it 
is expressed effectively in the infected cells [6, 7]. An impor-
tant property of M2 is the conservation of its sequence. The 
sequence of its extracellular domain (23 amino acid residues), 
M2e, remains practically unchanged for all type A viruses, 
which have been extracted from humans since 1933 [4, 8, 
9]. However, M2 exhibits a low immunogenicity, and after 
infection, the immune response against it is practically not 
activated [10].
The solution to the problem of the low immunogenicity 
of M2 lies in the protein attaching to the nanosized carrier 
particle. Such a nanovaccine, when imitating a pathogen, pos-
sesses high immunogenicity and is effectively recognized by 
the human immune system. W. Friers et al. used virus-like 
particles produced by the HBc antigen of the hepatitis B virus 
as a carrier for the M2e peptide [4, 11]. Mice immunization by 
M2eHBc particles produced in E. coli provided 100% protec-
tion against the lethal influenza infection [4]. Besides the HBc, 
virus-like particles based on the human papilloma virus can 
be used as carriers of the M2e [12], as well as bacteriophages 
Qβ [13], the papaya mosaic virus [14], and the cowpea mosaic 
virus [15]. 
As mentioned above, the sequence of M2e is highly con-
served in all human viral strains of Type A influenza; howev-
er, in animal strains it differs significantly [16, 17]. The M2e of 
the swine flu virus A/California/04/2009(H1N1), which was 
responsible for the 2009 pandemic, differs from the M2e of 
the human strain in 4 out of 23 amino acid residues (Table 1). 
Such differences may determine the specificity of vaccines 
based on M2e. In this work, we constructed recombinant par-
ticles (M2sHBc-particles) which carry the M2e viral peptide 
of the swine flu A/California/04/2009(H1N1) and showed 
that immunization with such nanoparticles provides full pro-
tection of vaccinated mice against the lethal challenge by 
swine flu virus A/California/04/2009(H1N1). At the same 
time, protection against the avian flu infection, strain A/
Duck/Potsdam1402-6/1986 or human strain A/PR/8/34, 
proved only partial, which emphasizes the necessity of tak-
ing into account the sequence differences of M2e of influenza 
strains of different origins when developing universal influ-
enza vaccines. 
EXPERIMENTAL PART
Construction of expression vector pQE-M2sHBc and E. coli 
producer strain. 
The gene that codes for the hybrid protein M2sHBc was syn-
thesized using a three-step PCR. During the first step, the 
portion of the M2HBc sequence was obtained as a result of 
PCR with the primers M2F3 (C GAA TGG GAA TGC CGT 
TGC AGC GAT AGC AGC GAT GAC CCT) and HBC-R2 (A 
GGA TCC TCA GCA AAC AAC AGT AGT CTC CGG AAG) 
and DNA copy of the hepatitis B virus genome as a template. 
During the second step, the obtained fragment was used as 
a template for the PCR with the primers M2sF1 (GAA ACC 
CCG ACC CGT AGC GAA TGG GAA TGC CGT TGC AGC) 
and HBC-R2. During the third step, a full-sized gene, M2sH-
Bc, was obtained as a result of the PCR amplification with the 
primers M2sF2 (CTC ATC AGC CTG CTG ACC GAA GTG 
GAA ACC CCG ACC CGT AGC) and HBC-R2. The fragment 
obtained, 525 bp, was digested with the restriction enzymes 
PagI and BamHI, whose recognition sites were entered into 
the sequence of primers M2sF2 and HBC-R2, respectively, 
and cloned into the expression vector pQE60 (Qiagen) using 
sites for NcoI and BamHI. The expression vector pQE-M2sH-
Bc was used in further work. Sequencing verified the absence 
of the PCR-specified mutations in the synthesized gene.
To obtain the producing strain of M2sHBc, plasmid pQE-
M2sHBc was introduced into the E. coli strain DLT1270 by 
transformation. Strain DLT1270, a derivative of the DH10B 
[18], contained the repressor gene for the lactose operon lacI 
integrated into a chromosome.
Isolation and purification of the M2sHBc-particles
Strain DLT1279/pQE-M2sHBc was grown in LB-broth until 
the midpoint of the logarithmic growth phase (OD600 = 0.5) at 
37 0C, then IPTG was added to 1mM, and the culture was left 
to continue to grow for 16 hours at 30 0C. Cells from the pro-
ducing strain were collected by centrifugation at 3,000 rpm 
for 30 minutes and were re-suspended in a 50 mM Tris-HCl 
buffer pH 8.0, which contained 0.5M NaCl, 15mM EDTA, and 
20% sucrose, calculating 1ml of buffer per 50ml of culture. 
Cell suspension was treated with lysozyme (1mg/ml) for 15 
min at 4 °C; afterwards, the cells were lysed by sonication. 
Polyethylene glycol (50% weight/volume) was added to the 
lysate solution (1/20 volume) and incubated for 30 min at 
4 °C. Next, it was centrifuged for 20 minutes at 13,000 rpm. 
Table 1. Sequence comparison of extracellular domains of M2 proteins of influenza strains of human and animal origins. Amino acids 
that change relative to the human influenza M2e consensus sequence are underlined. 
Host Strain  М2е peptide sequence
Swine/human A/California/04/2009 SLLTEVETPTRSEWECRCSDSSD
Human Consensus sequence SLLTEVETPIRNEWGCRCNDSSD
Human A/PR/8/34 SLLTEVETPIRNEWGCRCNGSSD
Avian A/Chicken/Kurgan/05/2005 SLLTEVETPTRNEWECRCSDSSD
Avian A/Duck/ Potsdam1402-6/1986 SLLTEVETPTRNGWECKCSDSSDRESEARCH ARTICLES
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A fifth of the volume of the concentrated solution of ammo-
nium sulfate was added to the supernatant, mixed and left to 
stand for 30 min at 4 °C. The produced protein precipitate was 
suspended in 1ml of the same buffer and precipitated with 
ammonium sulfate a second time under the same conditions. 
The produced precipitate was dissolved in a 1ml 50mM Tris-
HCl buffer with pH 8.0, which contained 0.5 M NaCl, 15mM 
EDTA, and 20% sucrose. The obtained preparation of M2sHBc 
particles contained, according to the SDS-PAGE, about 90% 
of the M2sHBc protein with a concentration of ~ 0.5 mg/ml.
Mice Immunization
To study the immunogenicity and the protectivity of the can-
didate vaccine, the immunization scheme was applied with the 
use of the TiterMax Gold Adjuvant (Sigma) at first immuniza-
tion and the incomplete Freund’s adjuvant (Sigma) at the fol-
lowing immunizations. Second immunization was conducted 
three weeks after the first, and the third was done the follow-
ing week. The immunization outline is shown in Table 2. 
Sera were collected 2 weeks after the third immunization, 
and the antibody titers were determined in the pooled sera of 
mice of each group (3-5 mice). As negative control, the serum 
of nonimmunized mice was used. As positive control, mono-
clonal antibodies to the M2e peptide strain A/Duck/Pots-
dam/1402-6/1986 (H5N2) were used: they were provided 
by P.G. Sveshnikov (Russian Research Center of Molecular 
Diagnostics and Therapy).
Synthetic Peptides 
As a standard for the determination of M2e antibody syn-
thetic peptides G-11-1 (SLLTEVETPTRNEWECRCSDSSD, 
corresponding to M2e of strain A/Chicken/Kurgan/05/2005), 
G19 (SLLTEVETPTRNGWECKCSDSSD, corresponding 
to the M2e of strain A/Duck/Potsdam1402-6/1986), G26 
(SLLTEVETPTRSEWECRCSDSSD, corresponding to the 
M2e of strain A/California/04/2009), and G18 (SLLTEVET-
PIRNEWGCRCNDSSD, corresponding to M2e of strain A/
PR/8/34) were used. 
ELISA for the titer determination of specific antibodies 
For ELISA, 96-well plates with a high sorption capacity 
(Greiner, Germany) were covered with synthetic peptides 
G-11-1, G19, G26, and G18 with a concentration of 5 mg/
ml (in the carbonate buffer, pH 9.5-9.6) and kept overnight 
at 4 °C. Plates were treated with a blocking buffer (0.01 M 
PBS pH 7-7.4) with 5% FCS for 1 hour at room tempera-
ture and washed 3 times with PBS-Tween. The pooled mice 
sera from each group were analyzed in duplicates. 100 μl of 
2-time serum dilutions were added to the well plates (start-
ing with 1:400) in the blocking buffer then incubated for 1 
hour at room temperature. As a conjugate, rabbit polyclonal 
anti-mice IgG (Abcam, Great Britain) were used in a 1:8,000 
dilution, marked with a horseradish peroxidase. ТМB was 
used as a substrate. The reaction was monitored by UV-Vis 
spectroscopy at 450 nm. The last dilution of the serum, which 
had an optical absorption at least twice higher than that of 
nonimmunized mice, was taken as an antibodies titer.
Viruses and mice infection
For the infection of the animals immunized by the candi-
date vaccines, the following influenza viruses, adapted to the 
mice, were used: A/Duck/Potsdam/1402-6/1986(H5N2), A/
California/04/2009 (H1N1), and A/PR/8/34 (H1N1). The vi-
rus was administered intranasally in a total volume of 50 μl 
containing 5LD50 to mice anesthetized by ether. The animals 
were observed daily after infection. The protective properties 
of the candidate vaccine were evaluated based on two pa-
rameters: determination of body weight dynamics and mice 
survival after infection.
RESULTS AND DISCUSSION
Design and production of M2sHBc nanoparticles
The Hepatitis B nuclear antigen is one of the most effective 
carriers of antigen determinants. Monomers of this protein, 
consisting of 183 amino acid residues, self-assemble into icosa-
hedral particles with a 34 nm diameter, made of 240 subparti-
Table 2. Evaluation of immunogenicity and protectivity of the candidate vaccine based on the M2e peptide of the swine influenza virus. 
Group of 
mice
Number 
of mice
First 
immunization 
Second 
immunization
Third 
immunization
Influenza virus challenge
A/Duck/
Potsdam/1402-6/1986 
(Н5N2)
A/California/
04/2009 (H1N1) A/PR/8/34
Experimental 
(М2sНВс)  60
60 mice with 
TiterMax Gold 
Adjuvant 
50 g/mice s.c.*
60 mice with 
Freund’s incom-
plete adjuvant 
50 g/mice s.c.
60 mice with 
Freund’s incomplete 
adjuvant 
50 g/mice s.c.
20 mice
5 LD/50
20 mice
5 LD/50
10 mice
5 LD/50
Control 40 PBS PBS PBS 15 mice
5 LD/50
15 mice
5 LD/50
10 mice
5 LD/50
* - subcutaneous injection 74 | ACTA NATURAE |  VOL. 2  № 2 (5)  2010
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cles organized in dimeric blocks [19]. Two HBc antigen regions 
can be used for the presentation of foreign peptides on the 
surface of the HBc particles – the protein N-terminus and 
the immunodominant loop located between the 75th and 85th 
amino acid residues of the protein [20-22]. Based on our expe-
rience, the introduction of the foreign sequence into the im-
munodominant loop results, in most cases, in the disturbance 
of the assembly and/or the solubility of the particles. There-
fore, as a site for the introduction of the M2e peptide for the 
construction of the hybrid protein M2sHBc, the N-terminus 
of HBc was used. The HBc sequence contains an arginine-rich 
C-terminal domain, which binds viral DNA during the viron 
assembly. When expressed in E. coli, this domain binds bacte-
rial RNA [23], whose presence in the preparation is undesired. 
Since the C-terminal domain (150 – 183 amino acid residues) 
is not necessary for the assembly of the particles [24], it was 
removed and replaced by a cysteine residue, whose introduc-
tion increases the stability of HBc particles [16]. Therefore, 
our hybrid protein M2sHBc comprises, starting from the N-
terminus, the sequence of M2e peptide of the swine flu virus 
A/California/04/2009 (H1N1), the sequence of HBc antigen 
from the 4th to 149th amino acid residues, and the C-terminal 
cysteine. 
The gene coding for the hybrid protein M2sHBc was syn-
thesized using three-stage PCR with the HBc sequence as 
a template. During each stage, the sequences encoding the 
regions of M2e were added to the 5’-end of the synthetic 
gene. The obtained synthetic gene M2sHBc was cloned in 
the expression vector pQE60 (Qiagen) under the control of 
the promoter, inducible by IPTG. The hybrid protein is well 
expressed in E. coli (Figure 1A) and mainly present in the 
soluble fraction. The assembly of M2sHBc in virus-like nano-
particles was confirmed by electron microscopy of a purified 
specimen (Figure 1B). 
Immunogenicity of the M2sHB particles
Mice immunization with the purified preparation of M2sHBc 
particles was done to characterize their immunogenicity and 
protectivity. The test group that consisted of 60 animals was 
immunized subcutaneously, using TiterMax Gold Adjuvant 
(Sigma) for the first vaccine introduction, and the Freund’s 
adjuvant (Sigma) for the consecutive immunizations. To test 
the immunogenicity of the candidate vaccine, the mice sera 
were analyzed two weeks after the first and the third immu-
nizations and antibody titers were determined in the pooled 
mice sera from each group (3-5 mice). To perform ELISA, we 
used four synthetic peptides whose sequences corresponded 
to the M2e of the swine flu virus A/California/04/2009, two 
strains of avian flu, and a human strain, A/PR/8/34. The re-
sults obtained (Table 3) show that after three immunizations 
the serum antibodies of isotope IgG are produced in high tit-
Fig. 1. Expression 
and purification of 
М2sНВс particles.
(А) SDS-PAGE 
analysis of protein 
samples. 1 - 
molecular weight 
marker, kDa. 
2 - protein sample 
from the strain 
DLT1270/ pQE-
M2sHBc before 
the induction of 
М2sНВс expres-
sion. 3 - the same 
as in line 2, but 
after 16h induction 
of M2sHBc expres-
sion. 4 - purified 
M2sHBc particles
(В) Electron 
microscopy of 
М2sНВс particles. 
1
26
19
А
B
23 4
100 nm
Table 3. Titers of IgG antibodies against M2e in sera of immunized mice. 
Serum samples
Titers of antibodies recognizing synthetic M2e peptides
G-26 G-19 G-11-1 G-18
After first immunization  1600 1600 800 800
After third immunization 51200 51200 51200 6400
Positive control (monoclonal antibodies against G19 peptide, clone D2)  >51200 >51200 >51200 1600
Negative control (sera of nonvaccinated mice) <400 <400 <400 <400RESEARCH ARTICLES
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Fig. 2. Dynamics of body weight of mice after challenge with in-
fluenza virus A/California/04/2009 (H1N1). Data in the control 
are shown for survived mice.
ers. These antibodies bind both synthetic peptides G-26 of 
the swine flu A/California/04/2009 (H1N1), the sequence of 
which matched one in M2sHBc used for the immunization, as 
well as synthetic peptides, the sequences of which correspond 
to the M2e of heterological strains of the avian and human 
influenza. 
Protective action of the candidate vaccine
 In order to evaluate the effectiveness of the vaccine, mice in 
both the experimental and control groups were challenged 
with three influenza strains adapted to mice: A/Duck/Pots-
dam/1402-6/1986 (H5N2), A/California/04/2009 (H1N1), 
and A / PR / 8 / 34 (H1N1). Viruses were administered intra-
nasally at a dose of 5 LD50. 
Figure 2 shows the body weight loss dynamics of animals 
after infection with 5 LD50 of the swine flu virus A/Califor-
nia/4/2009, which could indicate the severity of the disease. 
The weight of the immunized animals dropped after infec-
tion (to 90% of the initial weight), but to a much lesser extent 
than that of mice in the control group (up to 70% of the initial 
weight). These results indicate that immunization with can-
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Fig. 3. Survival of mice immunized with M2sHBc, followed by a 
potentially lethal challenge with different mouse-adapted influ-
enza strains. 76 | ACTA NATURAE |  VOL. 2  № 2 (5)  2010
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didate vaccines will not prevent influenza infection, but that 
it will reduce the morbidity. 
The dynamics of mice death after infection with various 
influenza strains are shown in Fig. 3. The results suggest that 
M2sHBc provides complete protection after a triple immuni-
zation. Over the entire period of observation, all of the ani-
mals in this group survived, whereas in the control group of 
mice subjected to these same infection conditions only 12% 
of animals survived. Partial protection against infection was 
observed against influenza strains in which the amino acid 
sequence of the M2e peptide differs from the one used in 
the preparation for immunization. Thus, 60% of immunized 
animals survived upon infection with the avian flu A/Duck/
Potsdam/1402-6/1986 as opposed to 12% in the control group 
(statistical significance P <0.006, Fisher test). When infected 
with a “human” influenza strain A/PR/8/34, the survival 
rate of animals was 40% in the experimental group and 20% 
in the control. 
Prospects for the development of universal influenza vac-
cines based on M2e
The conservation of an amino acid sequence of the M2 protein 
has become a basis for the development of a universal influ-
enza vaccine. Since practically all type A influenza viruses iso-
lated from the human population have the same sequence of 
M2e, the prospects for the creation of such a vaccine are real 
[5]. However, strains of animal origin, such as the “swine flu” 
virus, that have appeared in recent years have differences in 
the M2e peptide sequence, and, as shown through our results, 
the effectiveness of an M2e-based vaccine against heterolo-
gous strains of influenza is lower. One of the ways to create 
a M2e vaccine effective against a wide range of influenza 
strains, both human and animal, can be through the inclusion 
of several copies of M2e peptide sequences corresponding to 
different types of M2e into the M2sHBc particles.
CONCLUSIONS
The purpose of this study was to develop a recombinant can-
didate vaccine against a new, highly pathogenic strain of the 
influenza A virus: the swine flu H1N1. We used an approach 
intended to design a nanovaccine in which an extracellular 
domain of the M2 protein of the influenza virus was intro-
duced on the surface of the virus-like particles formed by a 
nuclear antigen of hepatitis B. Our data show that the hybrid 
protein M2sHBc was efficiently expressed in E. coli and self-
assembled in nanosized virus-like particles. Mice immuniza-
tion with M2sHBc particles generates an effective immune 
response against M2e, and it ensures immunity against an 
influenza virus strain that has an identical M2e peptide se-
quence. Thus, M2sHBc particles can be used as a basis for the 
development of a recombinant vaccine against the modern 
pandemic swine flu H1N1 and other viruses whose appear-
ance is expected in the coming years. 
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